Awakn Life Sciences Enters Into Global Licensing Agreement For Sublingual Delivery Formulation Dec 20, 2023
Awakn’s Dr. Ben Sessa: Ketamine Assisted Therapy Providing “Breakthrough, Transformative Experience” Jan 31, 2023
Numinus Announces Strong Appointment Growth As Studies Demonstrate Ketamine Effectiveness For Depression Sep 20, 2022
Awakn Life Sciences Receives UK State Funding to Identify Optimal Pathway to Market in UK & US for Its Lead… Jul 5, 2022